J. B. Chemicals & Pharmaceuticals Limited

NSEI:JBCHEPHARM Voorraadrapport

Marktkapitalisatie: ₹271.5b

J. B. Chemicals & Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO J. B. Chemicals & Pharmaceuticals is Nikhil Chopra, benoemd in Dec2020, heeft een ambtstermijn van 3.92 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 71.34M, bestaande uit 49.2% salaris en 50.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.026% van de aandelen van het bedrijf, ter waarde ₹ 69.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 4.1 jaar.

Belangrijke informatie

Nikhil Chopra

Algemeen directeur

₹71.3m

Totale compensatie

Percentage CEO-salaris49.2%
Dienstverband CEO3.9yrs
Eigendom CEO0.03%
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur4.1yrs

Recente managementupdates

Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

Aug 15
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

Recent updates

We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

Nov 27
We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Nov 09
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price

Sep 24
J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price

Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

Aug 15
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 11
J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well

Jun 28
These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well

J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

Apr 19
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Feb 09
J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

Dec 22
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

Nov 29
We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25

Aug 03
J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25

J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50

Feb 11
J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50

Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?

Dec 03
Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?

A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

Sep 21
A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly

Aug 03
J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly

Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

Jun 15
Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?

Mar 29
Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?

J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50

Feb 16
J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50

Analyse CEO-vergoeding

Hoe is Nikhil Chopra's beloning veranderd ten opzichte van J. B. Chemicals & Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

₹6b

Jun 30 2024n/an/a

₹6b

Mar 31 2024₹71m₹35m

₹6b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹4b

Mar 31 2023₹65m₹37m

₹4b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹59m₹18m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹5b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹32m₹7m

₹4b

Compensatie versus markt: De totale vergoeding ($USD 846.14K ) Nikhil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 610.84K ).

Compensatie versus inkomsten: De vergoeding van Nikhil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Nikhil Chopra (51 yo)

3.9yrs

Tenure

₹71,338,000

Compensatie

Mr. Nikhil Ashokkumar Chopra serves as Chief Executive Officer and Whole-Time Director at J. B. Chemicals & Pharmaceuticals Limited since December 23, 2020 and has been its Director since May 10, 2020. He...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Nikhil Chopra
CEO & Whole-Time Director3.9yrs₹71.34m0.026%
₹ 69.9m
Suresh Amin
Assistant Vice President – Human Resourceno data₹10.48m0.0025%
₹ 6.7m
Narayan Saraf
Chief Financial Officerless than a year₹12.74mgeen gegevens
Kunal Khanna
President of Operationsno data₹28.44mgeen gegevens
Bhagwat Deora
Vice President of Finance & Accountsno data₹9.48mgeen gegevens
Suresh Bhise
Vice President of Information & Technology9.8yrs₹10.70mgeen gegevens
Sridhar Bharadwaj
Vice President of HR & Administration8.2yrs₹13.80m0.00084%
₹ 2.3m
Himanshu Ranvah
Vice President of Legal1.8yrs₹11.49mgeen gegevens
Pradeep Singh
President of Global Businessno data₹42.09m0.012%
₹ 31.5m
Parmeshwar Bang
Executive Vice President of Operations of Daman1.3yrs₹17.24m0.0048%
₹ 13.1m
Bhushan Sachdev
Executive Vice President of Supply Chain Operationsno data₹19.54m0.0084%
₹ 22.7m
Jason D'Souza
Executive Vice Presidentless than a year₹18.12m0.0032%
₹ 8.7m

1.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van JBCHEPHARM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Nikhil Chopra
CEO & Whole-Time Director4.1yrs₹71.34m0.026%
₹ 69.9m
Shadrack Mapetla
Chairman of Biotech Laboratories (Pty ) Ltdno datageen gegevensgeen gegevens
Arun Duggal
Non-Executive Independent Chairmanless than a yeargeen gegevensgeen gegevens
Padmini Kaicker
Non-Executive & Independent Director4.3yrs₹7.50mgeen gegevens
Prashant Kumar
Non-Executive Director4.3yrsgeen gegevensgeen gegevens
Akshay Tanna
Non-Executive & Non-Independent Directorless than a yeargeen gegevensgeen gegevens
Gaurav Trehan
Non-Executive Director3.8yrsgeen gegevensgeen gegevens
Sumit Bose
Non-Executive & Independent Director4.3yrs₹7.50mgeen gegevens

4.1yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van JBCHEPHARM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).